TechSeeker Profile

XOMA Corporation (AKA: XOMA Ltd)
Profile last edited on: 4/12/2018

discovery, development and manufacture of therapeutic antibodies.
TS Type
Former SBIR
Year Founded
Last Involved Year

Key People / Management

  Susan Kramer -- Vice President, Project a

  Svetlana Lucas -- Director of Business Deve

  Thomas E Smart -- Vice President, Business

  Diane Wilcock -- Director Intellectual Pro

Location Information

2910 Seventh Street
Berkeley, CA 94710
   (510) 204-7200

Public Profile

XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies to treat inflammatory, autoimmune, infectious, and oncological diseases. The company receives royalties on products, such as LUCENTIS for the treatment of neovascular (wet) age-related macular degeneration; and CIMZIA for the treatment of rheumatoid arthritis and Crohn’s disease. Its products under development include XOMA 052, a monoclonal antibody for the treatment of Type 2 diabetes, rheumatoid arthritis, gout, and other diseases, which is in Phase II clinical studies; and XOMA 3AB, a biodefense anti-botulism antibody for the treatment of botulism poisoning. The company’s developing product also includes HCD122, a human anti-CD40 antagonist antibody for the treatment of B-cell mediated diseases, including malignancies and autoimmune diseases in Phase I/II clinical trials for various indications. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. The company has collaboration agreements with Kaketsuken; National Institute of Allergy and Infectious Diseases; SRI International; Genentech, Inc.; UCB Celltech; Takeda Pharmaceutical Company Limited; Schering-Plough Research Institute; Novartis AG; and Arana Therapeutics Limited.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Privately Held
Stock Info
Received SBIR $$

Techseeker firm in the news

There are no news available.